Echelon Wealth Partners Comments on Medexus Pharmaceuticals Inc.’s Q2 2024 Earnings (TSE:MDP)

Medexus Pharmaceuticals Inc. (TSE:MDPFree Report) – Stock analysts at Echelon Wealth Partners reduced their Q2 2024 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Wednesday, September 6th. Echelon Wealth Partners analyst S. Quenneville now expects that the company will post earnings of $0.05 per share for the quarter, down from their prior estimate of $0.07. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.05 per share. Echelon Wealth Partners also issued estimates for Medexus Pharmaceuticals’ FY2024 earnings at $0.07 EPS.

Separately, Bloom Burton upgraded Medexus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, June 26th.

Read Our Latest Report on Medexus Pharmaceuticals

Medexus Pharmaceuticals Stock Up 7.5 %

TSE:MDP opened at C$3.30 on Friday. The company has a 50 day simple moving average of C$2.53. The company has a market capitalization of C$67.35 million, a price-to-earnings ratio of 15.71 and a beta of 1.76. Medexus Pharmaceuticals has a 12-month low of C$0.88 and a 12-month high of C$3.53.

Medexus Pharmaceuticals (TSE:MDPGet Free Report) last posted its quarterly earnings data on Wednesday, June 21st. The company reported C$0.41 earnings per share for the quarter, topping the consensus estimate of C($0.07) by C$0.48. Medexus Pharmaceuticals had a return on equity of 16.23% and a net margin of 2.80%. The company had revenue of C$38.72 million during the quarter, compared to analysts’ expectations of C$38.17 million.

About Medexus Pharmaceuticals

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Read More

Earnings History and Estimates for Medexus Pharmaceuticals (TSE:MDP)

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.